Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EPI 12323

Drug Profile

EPI 12323

Alternative Names: EPI-12323; Naturasone

Latest Information Update: 29 Jun 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EpiGenesis Pharmaceuticals
  • Class Antiasthmatics; Small molecules; Steroids
  • Mechanism of Action Adenosine deaminase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 09 Jul 2013 Discontinued - Phase-I for Allergic rhinitis in USA (Inhalation)
  • 09 Jul 2013 Discontinued - Phase-I for Asthma in USA (Inhalation)
  • 09 Jul 2013 Discontinued - Phase-I for Chronic obstructive pulmonary disease in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top